Today's Low
₹ 1,436.35
Today's High
₹ 1,463.95
52 Weeks Low
₹ 852.00
52 Weeks High
₹ 1,180.10
Lower
₹ 1,295.30
Upper
₹ 1,583.10
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other dosage forms consists of injectables and biosimilars. Cipla Limited has collaboration with CSIR-Indian Institute of Chemical Technology for the development of medication for the treatment of COVID-19; partnership with Karwa Ltd. for the commercialization of antibody detection kits for COVID-19; partnership with the Premier Medical Corporation Private Limited for the commercialization of the rapid antigen test kits for COVID-19; licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.
No Data Found
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 1,494.40 | 1,527.48 | 1,454.38 |
R3 | 1,484.25 | 1,480.60 | 1,446.79 |
R2 | 1,474.10 | 1,472.28 | 1,444.26 |
R1 | 1,456.65 | 1,453.00 | 1,441.73 |
Pivot | 1,446.50 | 1,444.68 | 1,446.50 |
S1 | 1,429.05 | 1,425.40 | 1,436.67 |
S2 | 1,418.90 | 1,417.08 | 1,434.14 |
S3 | 1,401.45 | 1,397.80 | 1,431.61 |
S4 | 1,384.00 | 1,361.88 | 1,424.02 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
100.00
Bearish
RSI
72.01
Bearish
ROC
-4.47
Bearish
UltimateOscillator
31.96
Neutral
Williams Indicator
-97.44
Bullish
CCI Indicator
-145.57
Bullish
MACD
-1,871.64
Bearish
Stochastic Indicator
5.45
Neutral
ATR
52.96
High Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|---|---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|---|---|---|
21-07-2023 | 8.50 | 425 | Final |
08-08-2022 | 5.00 | 250 | Final |
09-08-2021 | 5.00 | 250 | Final |
Date Of Conduct | Board Meeting Details |
---|---|
28-01-2025 | Quarterly Results |
29-10-2024 | Quarterly Results |
10-05-2024 | Audited Results & Final Dividend |
25-01-2024 | Quarterly Results |
22-01-2024 | Quarterly Results (Revised) |
27-10-2023 | Quarterly Results |
26-07-2023 | Quarterly Results |
12-05-2023 | Audited Results & Quarterly Results & Final Dividend |
25-01-2023 | Quarterly Results |
04-11-2022 | Quarterly Results |
29-07-2022 | Quarterly Results |
10-05-2022 | Dividend & Audited Results |
25-01-2022 | Quarterly Results |
26-10-2021 | Quarterly Results |
05-08-2021 | Quarterly Results |
14-05-2021 | Dividend & Audited Results |